14 years of historical data (2012–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Ascendis Pharma A/S currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 278.6x P/FCF, 6% below the 5-year average of 296.3x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $14.3B | $12.9B | $8.0B | $7.1B | $6.8B | $7.4B | $8.4B | $6.5B | $2.6B | $1.3B | $538M |
| Enterprise Value | $14.6B | $13.2B | $8.3B | $7.4B | $7.0B | $7.1B | $7.9B | $5.9B | $2.3B | $1.2B | $357M |
| P/E Ratio → | -54.69 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 17.57 | 18.68 | 21.92 | 26.58 | 133.82 | 947.34 | 1214.13 | 483.74 | 243.27 | 880.44 | 116.73 |
| P/B Ratio | — | — | — | — | 26.00 | 8.34 | 10.07 | 10.84 | 9.19 | 7.20 | 3.04 |
| P/FCF | 278.56 | 296.28 | — | — | — | — | — | — | — | — | — |
| P/OCF | 234.71 | 249.64 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 19.05 | 22.73 | 27.90 | 137.20 | 916.96 | 1143.29 | 441.76 | 217.00 | 752.76 | 77.58 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 302.15 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Ascendis Pharma A/S earns an operating margin of -18.9%. Operating margins have expanded from -170.8% to -18.9% over the past 3 years, signaling improving operational efficiency.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.1% | 85.1% | 87.8% | 83.4% | 76.3% | 54.7% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -18.9% | -18.9% | -76.7% | -170.8% | -1097.9% | -5808.6% | -4755.1% | -1695.1% | -1462.6% | -7290.3% | -1583.2% |
| Net Profit Margin | -31.7% | -31.7% | -104.0% | -180.5% | -1139.6% | -4931.6% | -6025.5% | -1630.0% | -1229.5% | -8097.8% | -1487.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -818.4% | -101.7% | -44.5% | -58.4% | -49.7% | -55.7% | -68.1% | -46.1% |
| ROA | -17.7% | -17.7% | -37.7% | -50.3% | -53.6% | -37.2% | -50.6% | -43.8% | -49.1% | -61.8% | -42.6% |
| ROIC | -69.1% | -69.1% | -105.4% | -106.5% | -77.8% | -68.2% | -129.9% | -899.3% | -5304.7% | — | — |
| ROCE | -51.9% | -51.9% | -154.6% | -197.2% | -82.8% | -47.3% | -42.5% | -49.9% | -66.2% | -61.3% | -49.1% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $256M ($871M total debt minus $616M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 2.35 | 0.24 | 0.11 | 0.06 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | 0.66 | -0.27 | -0.59 | -0.94 | -0.99 | -1.04 | -1.02 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 5.86 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.69 | -1.69 | -4.26 | -10.34 | -18.31 | -115.52 | -172.38 | -185.68 | -1218.56 | -1149.91 | -14584.00 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.04x means Ascendis Pharma A/S can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 0.95x to 1.04x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.04 | 1.04 | 1.17 | 0.95 | 1.29 | 8.03 | 14.02 | 12.74 | 7.53 | 8.61 | 13.67 |
| Quick Ratio | 0.76 | 0.76 | 0.84 | 0.67 | 1.11 | 7.28 | 14.02 | 12.74 | 7.53 | 8.61 | 13.67 |
| Cash Ratio | 0.58 | 0.58 | 0.62 | 0.54 | 1.03 | 6.80 | 13.61 | 12.46 | 7.14 | 8.22 | 13.40 |
| Asset Turnover | — | 0.53 | 0.31 | 0.32 | 0.05 | 0.01 | 0.01 | 0.02 | 0.03 | 0.01 | 0.02 |
| Inventory Turnover | 0.34 | 0.34 | 0.15 | 0.21 | 0.09 | 0.05 | — | — | — | — | — |
| Days Sales Outstanding | — | 83.18 | 166.90 | 49.09 | 84.95 | 103.24 | 20.32 | 21.94 | 0.21 | 44.85 | 22.74 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Ascendis Pharma A/S returns 0.1% to shareholders annually primarily through share buybacks.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 0.4% | 0.3% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 0.0% | 1.5% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.1% | 0.1% | 0.0% | 0.0% | 1.5% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $61M | $58M | $56M | $56M | $55M | $51M | $47M | $41M | $34M | $27M |
Compare ASND with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| ASNDYou | $14B | -54.7 | — | 278.6 | 85.1% | -18.9% | — | -69.1% | — |
| AGIO | $2.3T | -4.2 | — | — | 88.3% | -873.9% | -30.2% | -26.6% | — |
| VRTX | $126B | 32.4 | 26.6 | 39.5 | 86.2% | 39.1% | 22.5% | 22.8% | 0.8 |
| BBIO | $13B | -17.5 | — | — | 94.4% | -113.3% | — | — | — |
| BMRN | $12B | 34.3 | 18.2 | 16.4 | 77.1% | 16.6% | 5.7% | 7.4% | 1.0 |
| COGT | $6B | -15.2 | — | — | — | — | -73.7% | -66.4% | — |
| PTCT | $5B | 8.8 | 5.6 | — | — | 50.1% | — | — | 0.5 |
| MIRM | $5B | -196.4 | — | 87.3 | 80.8% | -4.2% | -8.6% | -5.1% | — |
| FOLD | $4B | -79.8 | 139.5 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| CRNX | $4B | -8.3 | — | — | 80.1% | -9534.5% | -40.2% | -37.8% | — |
| CORT | $4B | 43.5 | 78.6 | 26.7 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 14 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ASND stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonAscendis Pharma A/S's current P/E ratio is -54.7x. This places it at the 50th percentile of its historical range.
Based on historical data, Ascendis Pharma A/S is trading at a P/E of -54.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Ascendis Pharma A/S has 85.1% gross margin and -18.9% operating margin.